Targeted Therapies in Lung Cancer 2023 Live Patient Forum

Video Listing from the Targeted Therapies in Lung Cancer 2023 Live Patient Forum

Description: Leading oncologists and come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins.

To view all of the transcripts for this Live Patient Forum, Visit https://drive.google.com/drive/folders/1Y4H7a3WsUZqRL9V2PiIzdu2IbyMC3JrD?usp=drive_link

Video #	Speaker(s)	Video Title	Description	cancerGRACE.org URL
AM SESSION
1	Desai	Biomarkers in NSCLC	Dr. Aakash Desai gives a basic overview of biomarkers, and discusses which ones are important for patients with NSCLC.	https://cancergrace.org/post/program-targeted-therapies-forum-presented-english-2023-video-series
2	Desai	The Importance of Biomarker Testing: What is Liquid Biopsy?	Dr. Aakash Desai details the importance of biomarker testing, and discusses the method of liquid biopsy to do so.	https://cancergrace.org/post/program-targeted-therapies-forum-presented-english-2023-video-series
3	Desai	Current Recommendations and Best Practices for Biomarker Testing	Dr. Aakash Desai discusses the current recommendations for biomarker testing in patients with NSCLC, as well as best practices.	https://cancergrace.org/post/program-targeted-therapies-forum-presented-english-2023-video-series
4	Desai	Barriers to Biomarker Testing: Ordering Tests	Dr. Aakash Desai emphasizes the importance of physicians ordering biomarker testing for patients with NSCLC	https://cancergrace.org/post/program-targeted-therapies-forum-presented-english-2023-video-series
5	Desai	Barriers to Biomarker Testing: Cost and Insurance	Dr. Aakash Desai discusses how to address the issues of cost and insurance approval when obtaining biomarker testing	https://cancergrace.org/post/program-targeted-therapies-forum-presented-english-2023-video-series
6	Desai	Biomarker Driven Therapy for NSCLC	Dr. Aakash Desai discusses the administration of therapy for biomarkers, and how to overcome the gaps in administration, access, and affordability.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-video-series-2
7	Reuss	The Adaura Trial: The Effect on EGFR+ Treatment	Dr. Joshua Reuss discusses the ADAURA trial, which suggested Osimertinib as treatment for EGFR+ NSCLC.	Yes https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-video-series-2
8	Reuss	Key Points from the Adaura Trial: Osimertinib	Dr. Joshua Reuss examines important details learned during the ADAURA trial, including overall survival, reduced risk of brain mets, and side effects.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-video-series-2
9	Reuss	The Alina Trial for ALK+ NSCLC	Dr. Joshua Reuss gives a brief description of the ongoing Alina trial for patients with ALK+ NSCLC	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-video-series-2
10	Reuss	Neoadjuvant Treatment for Patients with NSCLC	Dr. Joshua Reuss examines data on neoadjuvant targeted therapy.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-video-series-2
11	Reuss	Immunotherapy for Patients with Resectable NSCLC and a Driver Mutation	Dr. Joshua Reuss explains why immunotherapy is not typically given to patients with resectable NSCLC and a driver mutation.	Yes https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-video-series-3
12	Reuss	Targeted Therapy Before Surgery in Patients with Resectable NSCLC and Driver Mutation	Dr. Joshua Reuss discusses considerations and questions for targeted therapy before surgery.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-video-series-3
13	Reuss	Treatment Options for Patients with Locally Advanced Unresectable NSCLC	Dr. Joshua Reuss discusses treatment options for patients with locally advanced NSCLC, and how to proceed while waiting for trial data.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-video-series-3
14	Reuss	The Role of the Patient as Advocate	Dr. Joshua Reuss discusses what the patient can do to advocate for themselves during treatment.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-video-series-3
15	Iyengar	Adding to Targeted Therapy: Current Statistics and Biology	Dr. Puneeth Iyengar looks at current statistics for methods of adding to targeted therapy, as well as giving an overview of biology in treatment.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-video-series-3
16	Iyengar	Local Therapy for Limited Metastatic NSCLC	Dr. Puneeth Iyengar discusses the concept of using local therapy as an additional treatment for limited metastatic NSCLC, including Stereotactic Body Radiation Therapy (SBRT).	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-video-series-4
17	Iyengar	Local Therapy for Patients After Frontline Therapy	Dr. Puneeth Iyengar discusses local therapy options for patients with metastatic disease who have received a front line therapy.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-video-series-4
18	Iyengar	Local Therapy for Patients with Oligoprogressive NSCLC	Dr. Puneeth Iyengar discusses local therapy treatment options for patients who have oligoprogressive disease.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-video-series-4
19	Iyengar	The Future of Local Therapy	Dr. Puneeth Iyengar examines what has been learned from studies, what still remains unanswered, and future directions of local therapy treatments for patients with NSCLC.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-video-series-4
AM Q&A
20	AM Q&A: Iyengar, Higgins, Lin, Desai, Reuss	Q&A: Can a Patient Receive SBRT if Unable to Hold Their Breath?	The panel discusses options for SBRT administration, and if treatment is affected if a patient is unable to hold their breath.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-qa-video-series
21	AM Q&A: Iyengar, Higgins, Lin, Desai, Reuss	Q&A: Does Radiation Increase Toxicity for Patients on Targeted Therapy?	The panel discusses whether or not adding radiation will increase toxicity in patients who are already receiving targeted therapy.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-qa-video-series
22	AM Q&A: Iyengar, Higgins, Lin, Desai, Reuss	Q&A: What Targeted Therapy Options Exist for Patients with Driver Mutations?	The panel discusses targeted therapy options for patients who have driver mutations.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-qa-video-series
23	AM Q&A: Iyengar, Higgins, Lin, Desai, Reuss	Q&A: Is Biomarker Testing Common in Early Stage NSCLC?	The panel discusses the importance of biomarker testing even in early stage NSCLC.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-qa-video-series
24	AM Q&A: Iyengar, Higgins, Lin, Desai, Reuss	Q&A: Are There Ongoing Trials for Rare NSCLC Mutations?	The panel discusses trial and treatment information for rare lung cancer mutations.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-qa-video-series
25	AM Q&A: Iyengar, Higgins, Lin, Desai, Reuss	Q&A: Should Biomarker Testing Be Performed on Patients with Squamous Cell Lung Cancer?	The panel discusses whether a patient with squamous cell lung cancer should undergo biomarker testing.	Yes https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-qa-video-series
26	AM Q&A: Iyengar, Higgins, Lin, Desai, Reuss	Q&A: Resistance on Targeted Therapy: What Questions Should a Patient Ask Their Doctor?	The panel discusses what a patient should discuss with their doctor if they progress on a targeted therapy.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-qa-video-series
27	AM Q&A: Iyengar, Higgins, Lin, Desai, Reuss	Q&A: What Are Some Local Therapy Options for Patients with NSCLC?	The panel discusses local therapy options for patients with oligoprogression, and in particular, radiofrequency ablation for adrenal nodules.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-qa-video-series
28	AM Q&A: Iyengar, Higgins, Lin, Desai, Reuss	Q&A: What Can Patients Do to Close the Biomarker Testing Gap?	The panel discusses how patients can advocate for biomarker testing.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-qa-video-series
29	AM Q&A: Iyengar, Higgins, Lin, Desai, Reuss	Q&A: What Do We Know About Prevention and Causes of Lung Cancer?	The panel discusses current understanding of what can cause lung cancer, and prevention methods.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-qa-video-series
30	AM Q&A: Iyengar, Higgins, Lin, Desai, Reuss	Q&A: What Are the Platform Options for SBRT?	The panel discuss methods of delivering SBRT, including CyberKnife.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-qa-video-series-3
31	AM Q&A: Iyengar, Higgins, Lin, Desai, Reuss	Q&A: Why Can Some Patients Remain on TKIs Without Acquiring Resistance?	The panel discuss if there's a reason some patients can remain on TKIs for extended time without developing resistance.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-qa-video-series-3
32	AM Q&A: Iyengar, Higgins, Lin, Desai, Reuss	Q&A: Should a Patient with High PD-L1 Wait for Genetic Testing Results Before Starting Treatment?	The panel discusses the importance of knowing genetic testing results regardless of PD-L1 level.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-qa-video-series-3
BREAKOUT SESSIONS
33	Nagasaka	Treatment Options and Study Data for Patients with ALK+ NSCLC	Dr. Misako Nagasaka gives an in-depth discussion on ALK+ NSCLC, from possible treatment options to study data.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-breakout-sessions
34	Nagasaka	Treatment Options and Study Data for Patients with ROS1+ NSCLC	Dr. Misako Nagasaka details treatment options and study data for patients with ROS1+ NSCLC.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-breakout-sessions
35	Liu	Rare Fusions in NSCLC: RET	Dr. Stephen Liu discusses how RET fusions are detected, and discusses methods of treatment, including Selpercatinib and Pralsetinib.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-breakout-sessions
36	Liu	RET Fusion Treatment: Selpercatinib	Dr. Stephen Liu discusses Selpercatinib as a a treatment option for RET+ disease.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-breakout-sessions
37	Liu	RET Fusion Treatment: Pralsetinib	Dr. Stephen Liu discusses Pralsetinib as a treatment option for RET+ disease.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-breakout-sessions
38	Liu	Safety and Toxicity of Selpercatinib Versus Pralsetinib	Dr. Stephen Liu compares selpercatinib and pralsetinib as treatment options for patients with RET+ disease.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-breakout-sessions-2
39	Liu	The Future of RET+ NSCLC Treatment	Dr. Stephen Liu discusses recent developments in RET+ NSCLC treatment, including next-generation RET TKIs.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-breakout-sessions-2
40	Liu	NTRK+ NSCLC: Treatment Options and Side Effects	Dr. Stephen Liu gives an overview of treatment options for patients with NTRK+ NSCLC and what some side effects may be.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-breakout-sessions-2
41	Liu	NRG1 Fusions: Treatment Options	Dr. Stephen Liu discusses identifying and treating NRG1 fusions in NSCLC.	https://cancergrace.org/post/targeted-therapies-forum-presented-english-2023-breakout-sessions-2
42	Liu, Nagasaka/ Breakout 1 Q&A	Q&A: Is RNA Testing Available Commercially?	Drs. Stephen Liu and Misako Nagasaka discuss RNA testing.
43	Liu, Nagasaka/ Breakout 1 Q&A	Q&A: Can Patients Use Off-Label Treatment Options for ROS1+ NSCLC?	Drs. Stephen Liu and Misako Nagasaka discuss using off-label treatments.
44	Liu, Nagasaka/ Breakout 1 Q&A	Q&A: How Effective is Cabozantinib for ROS1 After Progression on Crizotinib?	Drs. Stephen Liu and Misako Nagasaka discuss using cabozantinib, and its potential side effects.
45	Liu, Nagasaka/ Breakout 1 Q&A	Q&A: Is Alectinib an Option for Patients with DCTN1 ALK+ Disease?	Drs. Stephen Liu and Misako Nagasaka discuss using alectinib for a DCTN1 ALK fusion.
46	Liu, Nagasaka/ Breakout 1 Q&A	Q&A: Should a Patient with New Lesions Switch from Alectinib to Lorlatinib?	Drs. Stephen Liu and Misako Nagasaka discuss treatment options for a patient who has developed new brain lesions while on alectinib.
47	Liu, Nagasaka/ Breakout 1 Q&A	Q&A: Can Pemetrexed and Bevacizumab be used for Squamous Disease?	Drs. Stephen Liu and Misako Nagasaka discuss pemetrexed and bevacizumab use in squamous cell lung cancer.
48	Liu, Nagasaka/ Breakout 1 Q&A	Q&A: TKI Neoadjuvant Studies: Is Complete Pathological Response Possible?	Drs. Stephen Liu and Misako Nagasaka discuss current trends toward neoadjuvant TKI treatment options.
49	Liu, Nagasaka/ Breakout 1 Q&A	Q&A: When Should a Patient do Biomarker Retesting?	Drs. Stephen Liu and Misako Nagasaka discuss when patients should consider biomarker retesting, and briefly compare pralsetinib and selpercatinib
50	Liu, Nagasaka/ Breakout 1 Q&A	Q&A: Which First Line TKI Should Be Used for a Patient with Stage IV Disease and No Brain Mets?	Drs. Stephen Liu and Misako Nagasaka discuss what first line treatment options should be for a patient with stage IV disease and no brain mets.
51	Liu, Nagasaka/ Breakout 1 Q&A	Q&A: Does BRAF in Non-Smokers Respond to Immunotherapy?	Drs. Stephen Liu and Misako Nagasaka discuss immunotherapy treatments for BRAF+ non-smoking patients.
52	Liu, Nagasaka/ Breakout 1 Q&A	Q&A: RET Fusion, Lobectomy, and Chemo: Risk of Recurrence?	Drs. Stephen Liu and Misako Nagasaka discuss a RET patient's risk of recurrence after a lobectomy and chemo.
53	Preeshagul	EGFR Mutations in Advanced NSCLC	Dr. Isabel Preeshagul gives a brief overview of EGFR, and discusses the mutations in advanced NSCLC.
54	Preeshagul	Combination Therapy with Osimertinib for EGFR+ NSCLC	Dr. Isabel Preeshagul discusses treatment options that can be added to Osimertinib for EGFR+ NSCLC
55	Preeshagul	Resistance Mechanisms in EGFR+ NSCLC Treatment	Dr. Isabel Preeshagul examines how EGFR+ NSCLC develops resistance mechanisms.
56	Preeshagul	Post-Osimertinib Treatment Options for EGFR+ NSCLC	Dr. Isabel Preeshagul discusses options for EGFR+ NSCLC treatment after Osimertinib.
57	Preeshagul	The ADAURA Trial: 2023 Updates	Dr. Isabel Preeshagul discusses the ADAURA Trial, and what it means for treatment of patients with EGFR+ NSCLC.
58	Preeshagul	Neoadjuvant Osimertinib for Patients with Surgically Resectable EGFR+ NSCLC	Dr. Isabel Preeshagul discusses the NEOS Trial, which tested neoadjuvant Osimertinib.
59	Preeshagul	Metastatic EGFR+ NSCLC: Recent Developments	Dr. Isabel Preeshagul looks at several studies regarding treatment options for metastatic EGFR+ NSCLC, including Keynote 789, Everest, and Symphony: Blu 945.
60	Sabari	KRAS+ NSCLC: Details and Diagnosis	Dr. Joshua Sabari gives an excellent overview of KRAS+ NSCLC, including co-alterations.
61	Sabari	Challenges of Targeted KRAS Treatment and Current Treatment Options	Dr. Joshua Sabari discusses factors complicating KRAS treatment, and current options.
62	Sabari	Barriers to Drug Development for KRAS G12C+ NSCLC	Dr. Joshua Sabari discusses the barriers to creating drugs for KRAS G12C disease.
63	Sabari	KRAS G12C Inhibitors Versus Chemotherapy in Second Line: Current Studies	Dr. Joshua Sabari examines data related to the Codebreak 200 trial, as well as acquired resistance to KRAS G12C inhibitors.
64	Sabari	Krystal 7 Study: Adagrasib +/- Pembrolizumab for KRAS G12C+ NSCLC	Dr. Joshua Sabari discusses the Krystal 7 study, and gives a conclusion to his discussion on overall treatment options for KRAS+ NSCLC.
65	Preeshagul, Sabari/ Q&A	Q&A: How Do Oncologists Approach Compound EGFR Mutations?	Drs. Preeshagul and Sabari discuss how oncologists approach patients who have compound EGFR mutations.
66	Preeshagul, Sabari/ Q&A	Q&A: What do Oncologists do for Patients with Co-Alterations?	Drs. Preeshagul and Sabari discuss how they approach patients who have co-alterations such as P53.
67	Preeshagul, Sabari/ Q&A	Q&A: What are Treatment Options for Patients with Leptomeningeal Disease?	Drs. Preeshagul and Sabari discuss treatment options for patients with disease that has spread to the lining of the brain.
68	Preeshagul, Sabari/ Q&A	Q&A: What is the Efficacy of Amivantamab and Lazertinib?	Drs. Preeshagul and Sabari discuss the Chrysalis trial.
69	Preeshagul, Sabari/ Q&A	Q&A: Would a Patient with KRAS+ NSCLC and No Smoking History Benefit from Immunotherapy?	Drs. Preeshagul and Sabari discuss treatment options in the small group of patients with KRAS+ NSCLC and no smoking history.
70	Preeshagul, Sabari/ Q&A	Q&A: What Should Patients Know About Liver Toxicity in Treatment?	Drs. Preeshagul and Sabari discuss liver toxicities in patients receiving treatment for NSCLC.
PM SESSION
71	Ivy Elkins	An Introduction to Advocacy	Ivy Elkins tells a bit of her story, and discusses the many ways one can become an advocate.
72	Ivy Elkins	Advocacy Resources and Organizations to Know	Ivy Elkins discusses various groups that are important for advocates to be aware of, such as the Department of Defense's CDMRP, and how biomarker status affects advocacy.
73	Ivy Elkins	EGFR Resisters: An Advocacy Group	Ivy Elkins discusses the EGFR Resisters, a group she helped to start.
74	Dr. Laura Petrillo	Decreased Cancer Mortality: How Treatments Have Improved	Dr. Laura Petrillo briefly discusses how cancer mortality has been decreasing, and what that could mean for patients with long term treatment.
75	Dr. Laura Petrillo	Living with Advanced Cancer: Handling Uncertainty	Dr. Laura Petrillo discusses how patients handle uncertainty in their cancer treatments, as well as the importance of doctor-patient communication.
76	Dr. Laura Petrillo	What is Palliative Care?	Dr. Laura Petrillo explains the difference between palliative and end of life care, and discusses the need for early palliative care.
77	Dr. Laura Petrillo	The Goal of Palliative Care	Dr. Laura Petrillo discusses the overarching goals of palliative care, and how it can be utilized in cancer treatment.
78	Patel, Lin, Elkins, Petrillo/ Q&A	Q&A: Where Should Investments Be Made to Benefit Patients?	The panel discusses how oncologists can better help their patients during care, with emphasis on communication and access issues.
79	Patel, Lin, Elkins, Petrillo/ Q&A	Q&A: How Can We Close the Gap in Clinical Trials?	The panel discusses how to make clinical trials more accessible to patients.
80	Patel, Lin, Elkins, Petrillo/ Q&A	Q&A: How Can Oncologists Integrate Patient Advocates into Clinical Studies?	The panel discusses how patient advocates can be utilized to better conduct clinical studies.
81	Patel, Lin, Elkins, Petrillo/ Q&A	Q&A: What Can be Done for Lung Cancer Prevention Advocacy?	The panel discusses the importance of educating the public on lung cancer prevention, such as radon testing.
82	Patel, Lin, Elkins, Petrillo/ Q&A	Q&A: What are the Differences in Palliative and Hospice Care?	The panel discusses the differences between palliative and hospice care, and the importance of implementing palliative care.
83	Patel, Lin, Elkins, Petrillo/ Q&A	Q&A: Am I Increasing my Lung Cancer Risk with Campfires?	The panel gives a brief discussion on the effects of campfires, as well as other long term inhaled factors, on development of lung cancer.
84	Patel, Lin, Elkins, Petrillo/ Q&A	Q&A: How Do I Integrate Palliative Care Services?	The panel discusses how to integrate palliative care into treatment.
85	Patel, Lin, Elkins, Petrillo/ Q&A	Q&A: How do I Handle Side Effects?	The panel discusses what can be done to combat side effects of cancer treatment such as fatigue.